BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 21, 2008
View Archived Issues
Adventrx Restructures to Focus Efforts on ANX-530 and ANX-514
A year after lead product CoFactor (ANX-510) failed a Phase IIb trial, Adventrx Pharmaceuticals Inc. is restructuring to focus on its chemotherapy emulsion products, ANX-530 and ANX-514. (BioWorld Today)
Read More
'Not a Slam-Dunk': FDA Panel to Review New Version of Myozyme
Read More
Study Describes Partner in Crime for Bcr-Abl Kinase
Read More
Singapore's S*BIO Adds $26M for Phase II Studies in Cancer
Read More
Other News To Note
Read More
Clinic Roundup
Read More